foxo4-dri senolytic peptide human trial 2024 2025 Frontiers FOXO4-DRI alleviates age-related testosterone secretion
FOXO4 DRI alleviates age related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice Aging Heterogeneity of Cellular Senescence, Senotyping, and Targeting by Senolytics and Senomorphics in Lung Diseases[v1] FOXO4 DRI regulates endothelial cell senescence via the P53 signaling pathway PMC Senotherapy for chronic lung disease ScienceDirect FOXO4 DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53 serine 15 phosphorylation Communications Biology Senolytic Interventions for Type 2 Diabetes: Current Evidence and Future Directions
Pay in 4 interest-free payments of $6.49 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13




